On the heels of a highly successful trial for its blockbuster diabetes drug semaglutide in obesity, Novo Nordisk is prepping a Phase IIIa study for an oral formulation.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,